New Cholesterol Drugs Vastly Overpriced, Study Contends - (U.S. News & World Report via NewsPoints Desk)

  • Study data published in JAMA suggest that PCSK9 inhibitors are grossly overpriced, as reported US News & World Report.

  • In the study, the investigators updated a prior cost-effectiveness analysis using current list prices as well as the results of a clinical study of Amgen's Repatha.

  • The researchers noted that while adding PCSK9 inhibitors to statins would prevent 2.9 million more heart attacks than strokes than adding Zetia, the treatments were not cost-effective based on a threshold of $100 000 per life year gained.

  • "The price would have to be between $4000 and $5000 [per year] for it to be cost-effective," said study author Kirsten Bibbins-Domingo, adding "if you look in other countries, in Europe, for example, that is in fact where this drug is priced."

  • Commenting on the news, Josh Ofman, senior vice president of global value, access and policy at Amgen, stated "we think that their model is deeply flawed," noting that the population used in the model had a small number of cardiovascular events.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.

Reference Articles